BioNTech (BNTX) Q3 2026 earnings review
BioNTech raises its sales plan, but key cancer trials stumble
BioNTech raised its full-year sales plan after seasonal vaccine shipments and partner payments lifted the third quarter, while several cancer trials stumbled. Revenue fell 15% from a year ago, and profit per share excluding one-offs dropped 43% as cancer research spending climbed. Chief executive Ugur Sahin highlighted a new late-stage breast cancer trial with Gilead, but by our math the updated outlook leaves fourth-quarter sales down about 68%.
| Revenue | €1,289.2M -15.1% from a year ago |
|---|---|
| Profit per share, excluding one-offs | €1.76 -43.4% from a year ago |
| Cash and security investments | €16.2B €16.6B last quarter |
| Full-year revenue outlook | Raised €50M middle of the range: €1.8B (-37%) |
⚖️ Verdict: 🔴 Bearish
The story got worse because clinical setbacks hit two of the three drug types in BioNTech's cancer pipeline. A Phase 3 breast cancer trial for its lead targeted chemotherapy showed only a small benefit and higher lung side effects, putting its first planned cancer filing in doubt, while two late-stage mRNA cancer trials either stopped early or missed a primary goal. On the positive side, the company handed future research costs for its Roche cancer vaccine over to its partner starting in 2027.
The question now is whether the remaining pipeline — led by the bispecific drug pumitamig and lung cancer candidate gotistobart — can make up for setbacks in mRNA and targeted chemotherapy. If gotistobart's Phase 3 lung cancer trial succeeds at its upcoming review and the uterine cancer filing goes ahead, the 2030 launch plan stays intact; if those slip, the company will burn cash for longer before replacing vaccine sales. The independent review of gotistobart and the DualityBio filing decision later in 2026 will tell.
🐂 Bull Case
Lead Cancer Drugs Advance in Late-Stage Trials
Chief executive Ugur Sahin said "our combination therapy strategy continues to gain momentum, underscored by the announced first global Phase 3 trial of pumitamig in combination with an antibody-drug conjugate". Pumitamig is an experimental cancer drug that blocks two tumour pathways at once, developed with partner Bristol Myers Squibb. While rivals test similar drugs, BioNTech is pairing pumitamig with targeted chemotherapies across seven late-stage trials.
In the third quarter, the German biotechnology group agreed with Gilead Sciences to test pumitamig alongside Gilead's drug in a Phase 3 breast cancer trial. Separately, early results from another experimental lung cancer drug, gotistobart, showed it "nearly doubled median overall survival" compared with standard chemotherapy.
What to watch: an independent review of the Phase 3 gotistobart lung cancer trial, expected before the end of 2026. If the committee recommends unblinding the study early, it would give the pipeline a near-term approval path.
Roche Deal and Buybacks Protect the Cash Pile
BioNTech holds €16.2 billion in cash and investments, and management is trimming costs to preserve that balance while funding late-stage trials. The company exercised an option in its cancer vaccine partnership with Roche so that "future R&D costs related to the program will be generally assigned to Roche/Genentech effective January 1, 2027".
In exchange for handing over the research bill, the vaccine maker will collect royalties if the drug reaches the market. Meanwhile, management spent €272 million on share buybacks in the third quarter, bringing total repurchases since May to €404 million, though prior shares issued to buy rival CureVac still pushed the diluted share count up 3.7% from a year ago.
What to watch: the initial research and development spending plan for 2027, which arrives with fourth-quarter results in March 2027. A lower spending target would prove that handing off the Roche trial costs and closing factories are reducing cash burn.
🐻 Bear Case
Breast Cancer Trial Setback Clouds the First Launch
Sahin said the company is advancing toward becoming a multi-product drugmaker by 2030, and trastuzumab pamirtecan — a targeted chemotherapy developed with DualityBio — was meant to be its first cancer launch. Management had previously planned to apply for US approval in uterine cancer this year, after delaying that filing from 2025.
In October, a Phase 3 breast cancer trial of the drug met its main goal, "demonstrating a statistically significant, yet modest improvement in progression-free survival" over standard chemotherapy. However, more patients suffered lung inflammation, including fatal cases, and the company admitted the results "suggest that the potential benefit to patients would be limited".
That weak result undercuts the drug's commercial promise, so BioNTech and its partner are now reviewing all breast and uterine cancer data before deciding on next steps and any approval filing. What to watch: the final decision with DualityBio on whether to submit the uterine cancer application, which will show if the first cancer launch is delayed again.
Two Late-Stage mRNA Cancer Trials Hit Roadblocks
Messenger RNA (mRNA) — the genetic technology behind BioNTech's COVID-19 shot — is one of the three pillars of its cancer strategy. Management said its conviction in the technology for cancer remains unchanged, even as co-founders Sahin and Özlem Türeci prepare to leave the executive board to lead a separate mRNA company.
Yet two clinical setbacks hit the mRNA cancer pipeline this quarter. The company and partner Roche stopped a Phase 2 colon cancer trial of autogene cevumeran, a tailored cancer vaccine, early, and BioNTech opted out of sharing future research costs for that drug starting in 2027. Separately, a Phase 3 head-and-neck cancer trial of another mRNA candidate, BNT113, "did not demonstrate a statistically significant improvement in PFS versus pembrolizumab alone", missing one of its two main goals.
What to watch: the final overall survival readout from the continuing BNT113 trial. A failure to extend patient lives would leave the company without a late-stage win in its original technology.
Higher Outlook Still Points to a Weak Fourth Quarter
Finance chief Ramón Zapata said "Our performance in the third quarter allowed us to narrow our full-year 2026 revenue guidance to the upper end of the previous guidance range". The company lifted the bottom of its full-year sales plan by €100 million, to €1.7–1.9 billion, after third-quarter revenue reached €1,289.2 million.
That third-quarter figure was Down 15.1% from a year ago, and it included a large partner payment from Bristol Myers Squibb that management had previously pegged at €613 million. By our math, subtracting €1,512.9 million of sales in the first nine months from the middle of the full-year plan leaves only €287 million for the fourth quarter, down 68.4% from €907.4 million a year earlier.
What to watch: fourth-quarter revenue on March 2, 2027. A reading near that €287 million mark would confirm that seasonal COVID-19 vaccine demand has shrunk far below last year's level.
Write-Downs and Cancer Trials Cut Into Profit
Reported net profit swung to €184.5 million from a loss of €28.7 million a year ago, only because last year's quarter included €678.5 million in legal settlement charges. Excluding one-offs, operating profit fell 48.1% to €381.4 million, and operating margin excluding one-offs dropped 18.8 percentage points to 29.6%.
- Research and development costs excluding one-offs: 44.9% of sales, up 13.3 percentage points from a year ago
- Sales and administrative costs: 13.8% of sales, up 4.1 percentage points on commercial build-up and CureVac
- Asset write-downs and restructuring charges: €242.9 million this quarter, excluded from adjusted profit
What to watch: non-operating write-downs and restructuring charges in the fourth quarter. Another large gap between reported and adjusted results would show that pipeline cuts are still costing money before savings arrive in 2029.
Risks this quarter didn't answer
Four standing concerns received no new numbers in the third-quarter release, leaving key parts of the transition unreadable until the full filing or year-end call.
- Vaccine vs partner sales: the release did not split €1,289.2 million of Q3 revenue between COVID-19 shots and the Bristol Myers Squibb collaboration.
- Co-founders' mRNA spin-off: no update on binding agreements or what technology and financial terms BioNTech will give the new company.
- Total late-stage trial count: the release did not update the company-wide count of ongoing pivotal trials (14 in Q2) needed for the 2030 launch target.
- Factory exits: no update on headcount reductions or the planned early-2027 exit of the Singapore site.
💲 Other KPIs
Contract liabilities — cash received from partners and customers for work not yet recognized as revenue — fell 24.8% from last quarter and 38.5% from a year ago. After holding near €830–846 million for three quarters, the balance dropped by €205.8 million by our math as BioNTech booked revenue from its Bristol Myers Squibb partnership.
Free cash flow — operating cash flow minus €33.6 million of property and equipment purchases — swung to an outflow of €163.4 million by our math, down from an inflow of €744.8 million a year ago. Despite reporting positive net profit, the German group used €129.8 million in operating cash because trade receivables rose by €489.1 million on seasonal vaccine shipments.
Gross margin — the share of sales left after the cost of making the products — rose 1.8 percentage points from a year ago to 92.0% by our math, rebounding from 8.1% in the second quarter. Cost of sales fell to €103.3 million as high-margin partner revenue and seasonal vaccine deliveries took a larger share of the quarter's sales.
🔮 Guidance
Raised. BioNTech lifted the bottom of its full-year outlook by €100 million, raising the middle of the range by €50 million to €1.8 billion (a 37.3% drop from 2025). By our math, that leaves about €287 million for the fourth quarter, down 68.4% from a year ago. This €50 million raise follows a €400 million cut at the midpoint last quarter.
Unchanged. The plan keeps full-year research and development spending excluding one-offs at a middle of €2.15 billion, up 6.5% from 2025 by our math. With €1,582.7 million spent in the first nine months, the middle of the outlook leaves €567.3 million for the fourth quarter, up 12.3% from a year ago as late-stage cancer trials expand.
Unchanged. Management kept its sales and administrative cost outlook at a middle of €750 million, up 20.1% from 2025 on commercial preparation and the addition of CureVac. By our math, subtracting €527.1 million of nine-month spending leaves €222.9 million at the middle of the range for the fourth quarter, up 2.3% from a year ago.
❓ Key Questions
Will BioNTech still file for trastuzumab pamirtecan approval in 2026?
The Phase 3 breast cancer trial showed limited patient benefit and higher lung toxicity, and the company is now reviewing all data with partner DualityBio. Investors need to know if the planned 2026 US filing for uterine cancer is delayed again.
How much of Q3 revenue came from COVID-19 vaccines?
Third-quarter revenue of €1,289.2 million included a large collaboration payment from Bristol Myers Squibb that management previously estimated at €613 million. Without the exact split, investors cannot measure how fast underlying vaccine demand is shrinking.
What are the financial terms of the co-founders' mRNA spin-off?
Co-founders Ugur Sahin and Özlem Türeci plan to transition to an independent mRNA company by the end of 2026 using rights contributed by BioNTech, yet the release gave no update on binding agreements or retained ownership.
Why did BioNTech book €223 million in new asset write-downs?
The company recorded €169.6 million of research impairments and €42.2 million of other impairments in the third quarter alone for assets outside its focus. Naming the written-down programs would show which past deals or trials failed.